EQS-News: Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division
EQS-News: Marinomed Biotech AG / Key word(s): Strategic Company
Decision/AGM/EGM
Marinomed Biotech AG: Extraordinary general meeting approves sale of
Carragelose division
19. 12. 2024 / 12:39 CET/CEST
The issuer is solely responsible for the content of this announcement. ══════════════════════════════════════════════════════════════════════════
Marinomed Biotech AG: Extraordinary general meeting approves sale of
Carragelose division
• Required majority of shareholders vote in favour of the sale of the
Carragelose business unit
• Proceeds from the sale ensure implementation of the restructuring plan
and commercialization of the Marinosolv platform
• Dr. Karl Mahler elected to the Supervisory Board
Korneuburg, Austria, 19.
